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Abstract
There is increasing evidence that alcoholism runs in families suggesting that genetic factors may play a role. In support
 .  .of this hypothesis, the alcohol-preferring AA and the alcohol-avoiding ANA rat lines have been developed through
selective outbreeding. Numerous studies indicate that the endogenous opioid system may be involved in controlling ethanol
consumption. Changes in opioid peptides and opioid receptors have been described after ethanol intake. But, the influence
of ethanol on peptidolytic degradation of opioid peptides has been largely ignored, although the peptidase-mediated
metabolism of neuropeptides is known as an important regulatory site of peptidergic transmission. Neutral endopeptidase
 .  .24.11 NEP and angiotensin-converting enzyme ACE degrade neuropeptides, including enkephalin and are expressed in
the brain. Furthermore, a good correspondence between the regional distribution of NEP and opioid receptors in rat brain
has already been reported pointing to a possible role of NEP in regulating opioid peptides. For both enzymes studied, the
gene expression pattern was found to be in good agreement with the corresponding enzyme activities in the brain regions
investigated, showing the highest levels for both specific mRNAs and enzyme activities in the striatum. Differences in both
measured parameters were detected in distinct brain regions of AA and ANA rats. Furthermore, in some brain regions
discrepancies between ACE and NEP mRNA levels and the corresponding enzyme activities were observed. For example,
in olfactory bulb and striatum such discrepancies were found for both enzymes studied. In tegmentumrcolliculi a higher
NEP gene expression in AA rats was associated with a higher NEP enzyme activity compared to the amounts found in ANA
rats. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Epidemiological and experimental studies indicate
that genetic factors are involved in the predisposition
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w xto and in the development of alcoholism 1,2 . Selec-
tive breeding leading to alcohol-preferring and -non-
preferring lines of animals supports this hypothesis.
 .The alcohol-preferring AA and the alcohol-avoiding
 .ANA rat lines, selected for differential alcohol
drinking since 1960’s, provide an excellent tool for
the identification of physiological and biochemical
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parameters related to the regulation of alcohol drink-
w xing 3 . It is generally accepted that multiple genes
are acting in concert to either increase or decrease an
w xindividual’s vulnerability to alcoholism 4,5 . Indeed,
a number of different neurotransmitter and neuro-
modulator systems are known to be influenced by
w xethanol 6,7 . Among these the endogenous opioid
system is considered to be important in mediating
w xsome of the alcohol’s effects 4 . Animal and human
studies have shown that treatment with opioid antag-
w xonists can reduce ethanol consumption 8–10 , and
differences in both the density of m and d opioid
receptors as well as in the levels of opioid peptides
between the AA and ANA rats have been shown
w x11–13 . From these studies it seems likely, that more
than one component of the endogenous opioid system
is involved in controlling ethanol consumption.
Homeostasis of a system depends on its compo-
nents, their interaction and regulation by biosynthe-
sis, processing and degradation. Although the termi-
nation of peptidergic transmission includes receptor-
mediated internalization of neuropeptides, hydrolysis
of peptides by peptidases is accepted to represent a
major mechanism for terminating the peptidergic sig-
w xnal 14,15 . In regard to the opioid system the NEP
plays a key role in the inactivation of the opioid
peptide enkephalin, an endogenous ligand of opioid
w xreceptors, in the brain 16 . Furthermore, a parallel
distribution of NEP and m andror d opioid receptors
w xin different rat brain regions has been reported 17 .
Enzyme inhibitors have been shown to attenuate
ethanol consumption and in mice with a high prefer-
ence for ethanol an enhanced enkephalin degradation
w xin striatum has been detected 18,19 . Long term
treatment with ACE inhibitors leads also to a reduc-
tion in voluntary ethanol intake by animals, but the
underlying mechanism of this effect is much less
w xunderstood 37 . However, the enzyme is an integral
membrane peptidase that degrades among other neu-
ropeptides enkephalin and substance P in vitro and
w xexhibits enrichment at synaptic junctions 15 . Re-
cently, the brain ACE was shown to be involved in
central nociceptive mechanisms by interaction with
w xthe endogenous opioid system 20 .
Regulation of peptide-mediated signals by pepti-
dases suggests that these enzymes may, in turn, be
regulated by other signals. So far, there are only a
few studies describing peptidase regulation: Phorbol
diesters change the NEP expression in rabbit synovial
w xfibroblasts 21 and dopamine receptor agonists and
antagonists alter the gene expression of the neuropep-
tide processing enzymes PC1 and PC2 in rat pituitary
w x22 . It is not known whether ethanol can affect
extracellular peptide levels in the brain via alterations
in corresponding peptidase metabolism. But, studies
describing an effect of NEP and ACE inhibitors on
ethanol consumption point to a role of these pepti-
dases in mediating some of ethanol’s actions.
Thus, the objective of the present study was to
investigate the activity and gene expression of NEP
and ACE in different brain regions of the AA and
ANA lines of rats under alcohol-naive conditions.
The activity of NEP and ACE was determined by
HPLC analysis, whereas a quantitative RT-PCR ap-
proach allowed determination of the mRNA level of
those enzymes.
2. Materials and methods
2.1. Animals and dissection
 .Adult 10 weeks old male AA and ANA rats
 .Natl. Public Health Inst., Helsinki, Finland from the
62nd generation were housed and handled for 4
weeks in groups of two on a 12r12 h lightrdark
cycle with food and water available ad libitum. These
animals had never had any contact with alcohol. Ten
rats of each line were used for biochemical analysis
and two rats of each strain were used for the evalua-
tion of molecular-biological data.
Animals were killed by decapitation. The brains
were rapidly removed and dissected on chilled petri
dishes to obtain the brain regions thalamus, hip-
pocampus, bulbus olfactorius, striatum, auditory cor-
 .tex including amygdala and tegmentumrcolliculi
including ventral tegmental area and substantia ni-
.. w xgra as previously described 23 . The tissues were
frozen on dry ice and stored at y808C until use. For
determination of the enzyme activities brain regions
had to be pooled as followed: the olfactory bulb and
hippocampus from five animals were used for one
membrane preparation and the striatum, thalamus,
auditory cortex and tegmentumrcolliculi from 3 or 4
animals were used for one membrane preparation.
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2.2. Membrane preparations
Membrane preparations were done according to
w xthe procedure described 24 . In brief, tissues were
homogenized using a glass–teflon homogenizer in ice
 .cold 50 mM Tris buffer pH 7.4 , filtered through
nylon gaze and centrifuged for 20 min at 48C and
43,000=g. The remaining pellet was resuspended in
the same buffer. The suspension was incubated for 30
min at 248C in a shaking water bath in order to
degrade interfering endogenous opioids and then it
was centrifuged again. The final pellet was again
resuspended in buffer, containing 0.32 M sucrose and
stored in portions until use at y808C. The protein
concentrations of the membranes were measured ac-
w xcording to the method of Bradford 25 .
2.3. Determination of NEP and ACE acti˝ities
After centrifugation membranes were resuspended
 .in a 50 mM Tris-buffer pH 7.4 . 100 mM leu-en-
 .kephalin LENK was employed to measure NEP and
ACE activities. Parallel assays were run with D-ala2-
 .  .leu-enkephalin DALEK 100 mM as a substrate in
order to validate the measured NEP activities. The
following enzyme inhibitors were used for inhibition
of the accompanying enzymes: 10y4 M bestatin
 .Sigma, Deisenhofen, Germany for inhibition of
y6 aminopeptidases, 10 M lisinopril Merck-Sharp-
. y6Dohme, USA for inhibition of ACE and 10 M
 .phosphoramidon Sigma, Deisenhofen, Germany for
inhibition of NEP. A mixture of bestatin with lisino-
pril was used to yield NEP activity and for the
measurement of ACE activity the inhibitors bestatin
and phosphoramidon were used. For determination of
the ACE activities membrane preparations contained
1.5 mg proteinrml, whereas for the NEP measure-
ments a concentration of 0.5 mg proteinrml was
used. 50 ml of membrane preparation, substrates and
inhibitors were incubated in a final volume of 250 ml
at 378C for 30, 60 and 90 min, respectively. The
reactions were stopped by addition of 1r10 volume
of 0.35 M HClO at 08C. The measurement of NEP4
and ACE activity was carried out by product forma-
tion the tripeptides Tyr–Gly–Gly, respectively,
2 .  .Tyr–D-Ala –Gly with HPLC Shimadzu using an
isocratic elution system buffer consists of 0.15 M
NaClO and 0.01 M NaH PO , pH 2.2 with 4 or 6%4 2 4
.acetonitril . For separation a Nucleosil C-18 column
was used. The detection was done at 216 nm. The
enzyme activities were calculated from the areas of
the peaks of the corresponding degradation products
and were expressed as nmol tripeptiderminrmg pro-
tein.
2.4. RNA isolation and DNase treatment
Total RNA was prepared from tissue by a single
step method using Trizol Gibco BRL, Eggenstein,
.Germany according to the manufacturer’s instruc-
tions. The yield and purity of the RNA was deter-
mined spectrophotometrically by UV absorption at
260 nm.
Before quantitative RT-PCR all samples were
 .treated with RNase-free DNase 1 mlrmg total RNA
 .Promega, Heidelberg, Germany for 30 min at 378C.
The reaction was stopped by heat treatment for 10
min at 708C and the RNA was then purified by
phenolrchloroform treatment. Effectiveness of the
DNase treatment was routinely checked by a PCR
reaction without reverse transcription.
2.5. Re˝erse transcription-polymerase chain reaction
( )RT-PCR
RT-PCR for NEP was carried out using the EZ
rTth RNA PCR kit Perkin Elmer, Weiterstadt, Ger-
.many . 200 ng of total RNA were amplified by
RT-PCR in a final volume of 50 ml 1=EZ buffer,
including 300 mM of each deoxy-NTP, 2.5 mM
 .Mn OAc , 5 U rTth DNA Polymerase, 10 pmol of2
the biotinylated 5X-NEP primer and 10 pmol of the
3X-NEP primer. The mixture was overlaid with 15 ml
 .chill-out-wax Biozym, Hess. Oldendorf, Germany .
Following the RT-reaction at 588C for 30 min the
amplification profile consisted of an initial cycle of 2
min at 958C, then 40 cycles of the following protocol:
denaturation at 948C for 45 s, primer annealing at
558C for 45 s and extension at 728C for 1 min for the
first cycle with an extension time of 1 s per cyclus.
During the last cycle the primer extension lasted 7
min.
RT-PCR for ACE was carried out using the stan-
dard RT-PCR protocol of the Perkin Elmer RNA
PCR Kit. For each reaction 200 ng total RNA were
used. Reverse transcription was carried out using 50
pmol random hexamers per reaction, in the PCR 10
pmol of the biotinylated 5X-ACE primer and 10 pmol
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of the 3X-ACE primer were used. The PCR profile
consisted of an initial cycle of 2 min at 958C, then 40
cycles of the following protocol: denaturation at 948C
for 45 s, primer annealing at 678C for 45 s and
extension at 728C for 1 min for the first cycle with an
extension time of 1 s per cyclus. During the last cycle
the primer extension lasted 7 min.
For quantification of the gene expression RNA
standards were diluted prior to use in water and either
known amounts of both RNA standards for standard
.curve or 200 ng of total RNA with a known amount
of mutated RNA standard were mixed together.
Primers were constructed from the published cDNA
w xsequences of rat ACE gene 26 . The sequences of the
primers were biotin-5X-CGGCAAGGACTTCAG-
X  . XGATCAAGC-3 sense 5 -CACTGCTGAGCAGGT-
X  .TGAGACTG-3 antisense .
Primers were constructed from the published cDNA
w xsequences of rat NEP gene 27 . The sequences of the
primers were biotin-5X-AATCAGCTGCTCGACT-
X  . XGATCC-3 sense 5 -TTTTGCTTTCTGCACTGC-
X  .TAC-3 antisense .
2.6. Preparation of RNA standards
The PCR-fragments of the NEP and ACE genes
obtained by RT-PCR with RNA isolated from rat
striatum were cloned in a PCR II vector invitrogen,
.Leek, Netherlands as described by the manufacturer.
The mutated standard was created using the
Chameleon double-stranded, site-directed mutagene-
 .sis kit Stratagene, Heidelberg, Germany in such a
way that the mutated standard differed from the
sample DNA sequence by only one nucleotide.
The sequence of the mutation primer for ACE was
5X-CCACCACGAAATGGGCCAGATCCAGTATT-
TCATGC-3X. The C«G point mutation is indicated
boldprinted in the sequence.
The sequence of the mutation primer for NEP was
5X-CGCAATGTCATCCCTGACACCAGTTCCC-
GATACAG-3X. The G«C point mutation is indi-
cated boldprinted in the sequence.
Plasmid DNAs of the sample and mutated se-
quence were linearized with a restriction enzyme that
cleaves downstream of the inserted fragment. RNA
standards were prepared from these linearized plas-
mids by in vitro transcription. The RNA was diluted
to 1011 moleculesrml in water containing 1 Urml
 .RNasin Promega, Heidelberg, Germany and stored
at 48C until use. At these conditions RNA prepara-
tions were stable for about 3 weeks.
2.7. Quantification by solid-phase minisequencing
Quantification was done as described previously
w x28 . A scheme of the assay is shown in Fig. 1. 1r10
Fig. 1. Principle of the RT-PCR and solid-phase minisequencing
method. A mixture of the mutated and sample RNA is reverse
transcribed and amplified using one biotinylated and one unbi-
otinylated PCR primer. The PCR product is captured in strepta-
vidin-coated microtitration wells and denatured. The nucleotide
that differs between the two sequences is detected in the captured
DNA strand by two separate minisequencing reactions. In these
reactions a detection step primer annealing immediately 3X of the
variable nucleotide is elongated by TAQ DNA polymerase with
w3 xone single H -labeled NTP complementary to the nucleotide to
be detected. The ratio of the incorporated labels reflects the initial
w xratio of the two RNA sequences 31 .
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of the RT-PCR reaction was analyzed per minise-
quencing reaction. For one assay every sample was
loaded in parallel.
2.8. Statistics
All data were analyzed with Student’s t-test for
independent samples.
3. Results
A quantitative RT-PCR approach for the detection
 .of gene expression was chosen because i the mate-
rial from brain regions of individual rats was limited
 .and ii expression of several genes should be deter-
mined in parallel from the same material. The RT-
PCR technique allows sensitive detection of mRNA
species in a very low amount of starting material.
However, due to several factors direct quantification
of specific mRNA species using this approach is not
w xpossible 29 . The most accurate quantitation of RNA
can be obtained by competitive RT-PCR, where an
internal standard should be coamplified with the sam-
ple of interest in the same reaction. Because the
efficiency of the PCR depends on the primers as well
as both the sequence and the size of the template, the
internal standard should be as similar as possible to
w xthe sample of interest 30 . In our assays the internal
 .standard mutated RNA differed in sequence from
the sample RNA only by one nucleotide. RT-PCR is
performed with the sample RNA and a known amount
of standard RNA, and then the ratio between the two
coamplified sequences is determined by the solid-
phase minisequencing method. The results allow de-
termination of the absolute amount of investigated
w xmRNA species present in the samples tested 28,31 .
First, a standard curve was prepared by mixing 106
molecules of the standard RNA with mutated RNA
standard in ratios ranging from 0.01 to 10. Plotting of
the G rC ratio obtained in the minisequencingcpm cpm
 .test resulted in a linear standard curve Fig. 2 . The
G rC ratio is affected by some factors likecpm cpm
w3 xspecific activities of the H NTP’s used, specificity
of the DNA polymerase and a low amount of back-
w3 xground caused by misincorporation of H NTP.
Therefore, we used a standard curve in parallel with
each set of samples.
ACE mRNA levels and enzyme activities are
shown in Fig. 3a and b, respectively. Gene expres-
sion data and enzyme activities for the NEP are
shown in Fig. 4a and b, respectively. A comparison
of the specific mRNA moleculesrmg total RNA
revealed a significant higher mRNA level for ACE in
some brain regions compared to the NEP mRNA
levels in the corresponding brain regions Fig. 3a and
.Fig. 4a . In striatum and tegmentumrcolliculi be-
tween 2 and 5 times more ACE mRNA compared
Fig. 2. Standard curves obtained by quantitative RT-PCR for ACE and NEP. R values ratio of the cpm values obtained in the reaction
for detection of the mutated RNA sequence to that in the reaction for detection of the sample RNA sequence. The mean value and
 .variation range SD for three separate assays are shown.
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 .  .Fig. 3. Gene expression A and activity B of ACE in brain
regions of AA and ANA rats. Gene expression was measured by
 .quantitative RT-PCR ns2 , enzyme activity was determined by
 .degradation of leu-enkephalin measured by HPLC ns10 . Data
represent means"S.E.M. )Significant differences between the
two lines of rats in corresponding brain regions with p-0.05. B,
bulbus olfactorius; S, striatum; Th, thalamus; Hc, hippocampus;
aC, auditory cortex and TrC, tegmentumrcolliculi.
with the NEP mRNA level was detected. In the
hippocampus the amount of ACE mRNA was even
10 times higher than the NEP mRNA amount. Inter-
estingly, measurement of the corresponding enzyme
activities when enkephalin was used as a substrate
 .showed contrary results Fig. 3b and Fig. 4b . In all
investigated brain regions the NEP activity was more
than 2 times higher than the ACE activity. However,
comparison of the enzyme activities should consider
the very different K values for enkephalin factorm
.1000 better for NEP . Furthermore, ACE is known to
degrade several other peptides than enkephalin which
was used as a substrate in this study. This may
explain, at least in part, the observed discrepancies
between gene expression levels and measured en-
zyme activities.
For both enzymes studied the pattern of gene
expression levels is in good agreement with the cor-
responding enzyme activities in the brain showing the
 .  .Fig. 4. Gene expression A and activity B of NEP in brain
regions of AA and ANA rats. Gene expression was measured by
 .quantitative RT-PCR ns2 , enzyme activity was determined by
 .degradation of leu-enkephalin measured by HPLC ns10 . Data
represent means"S.E.M. )Significant differences between the
two lines of rats in corresponding brain regions with p-0.05. B,
bulbus olfactorius; S, striatum; Th, thalamus; Hc, hippocampus;
aC, auditory cortex and TrC, tegmentumrcolliculi.
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highest amounts in striatum. Furthermore, differences
in the measured parameters were also detected be-
tween the two lines of rats. The gene expression
studies of ACE revealed a significantly enhanced
mRNA level in olfactory bulb, striatum, thalamus and
tegmentumrcolliculi of AA rats, whereas for the
corresponding ACE enzyme activities an opposite
tendency was found. In tegmentumrcolliculi of AA
rats the ACE enzyme activity was even significantly
lower compared to ANA rats. For NEP the same
discrepancy was observed in olfactory bulb and stria-
tum, but a good correlation between gene expression
and enzyme activity could be detected in other brain
regions tested. Interestingly, in tegmentumrcolliculi
of AA rats a higher NEP gene expression was associ-
ated with a higher NEP activity compared to the
levels found in ANA rats.
4. Discussion
During the past decades evidence has been accu-
mulating that genetic factors are involved in the
w xpredisposition to alcoholism 1,2 . Rodent lines ex-
hibiting innate differences in alcohol preference are
used for identifying physiological and biochemical
parameters linked to alcohol preference or nonprefer-
w xence 33 . Numerous studies suggest that the endoge-
nous opioid system is one of the systems involved in
genetically determined drug consumption. Opioid re-
ceptor antagonists have been shown to decrease
ethanol self-administration in several experimental
w xparadigms 4 and specific opioid receptor types have
w xbeen suggested to be important for this effect 34 .
These experiments have led to the hypothesis that the
positive reinforcing effects of ethanol are in part
mediated by the opioid system. Indeed, differences in
components of this system have been detected in
distinct brain regions of alcohol-preferring and alco-
hol-nonpreferring animals. Autoradiographic studies
showed a significantly higher density of m-opioid
receptors in some brain regions of AA rats compared
w xto the corresponding regions of ANA rats 11 . These
areas included regions of the limbic system which are
thought to be particularly involved in the reinforcing
effects of drugs of abuse. Differences were seen in
the nucleus accumbens, the caudate and the ventral
 .tegmental area VTA . Dopaminergic neurons in the
VTA project to the nucleus accumbens as well as to
other mesocortical and mesolimbic areas involved in
reinforcement. Further evidence suggests that compo-
nents of the endogenous opioid system may play a
w xrole in the regulation of dopaminergic tone 5,35,36 .
Differences between AA and ANA rats in opioid
w xpeptide levels have also been described 13 . How-
ever, there are only a few studies investigating the
role of opioid-degrading enzymes in alcoholism.
Enkephalin, one of the opioid peptides, is rapidly
degraded in the brain by 4 peptidases: aminopepti-
 . dase N E.C. 3.4.17.3. , membrane-dipeptidase E.C.
.  . 3.4.13.11. , NEP E.C. 3.4.24.11. and ACE E.C.
. w x3.4.15.1. 32 . Whereas the first two enzymes are
rather nonspecific, the two latter hydrolyze specifi-
cally neuropeptides. Furthermore, the coexistence of
NEP and m- andror d-opioid receptors in the brain
of mammals has been already described, supporting
the hypothesis that NEP has a selective role in the
w xtermination of the enkephalinergic signal 17 . NEP
inhibitors were shown to attenuate ethanol intake in
alcohol-preferring mice which, in addition, were re-
ported to have an increased enkephalin-degrading
w xactivity in striatum 18,19 . From animal studies it is
known that ACE inhibitors can produce a significant
reduction in alcohol consumption and this effect is
not the result of an ACE inhibitor-induced alteration
w xin the pharmacokinetics of ethanol 37,38 . Recently,
the necessity of ACE inhibitors for the complete
w xprotection of exogenous met enkephalin from degra-
w xdation was described 39 . From our results it can be
concluded that ACE participates in enkephalin degra-
dation in rat brain regions. The rate of enzymatic
degradation of a specific substrate is determined by
the K - and the V -value of the enzyme studied.m max
Although the K value of ACE for enkephalin ism
1000 times less than the K value of NEP, them
 .amount of ACE V is high enough to account formax
0.2–0.5 times of the enkephalin hydrolysis when
 .compared to NEP Fig. 3b and Fig. 4b . This is in
good agreement with the gene expression data, where
2–10 times more ACE mRNA was measured com-
pared to NEP mRNA levels in different brain regions
 .Fig. 3a and Fig. 4a .
Nevertheless, it should be noticed that both en-
zymes degrade also other neuropeptides. Especially,
ACE is known to convert preferentially angiotensin I
to angiotensin II and to degrade bradykinin as well as
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w xsubstance P 40–42 . Therefore, the reduction of
ethanol intake by ACE- and NEP-inhibitors may in
part be mediated through their influence on the
degradation of other neuropeptides than enkephalin.
Although in most investigated brain regions of AA
rats an enhanced level of ACE and NEP mRNA was
found, the corresponding enzyme activities did not
 .show adequate differences Figs. 3 and 4 . This fact
was more pronounced for ACE than for NEP. The
reason for the differences between gene expression
and enzyme activity is still not clear, but differences
in post-transcriptional processes andror a higher
turnover as well as inactive forms of the enzymes
could be assumed. Similar discrepancies between gene
expression data and protein levels has been described
for the POMC system in AA and ANA rats. Despite
the higher content of POMC mRNA in the hypothala-
mus of the AA rats, the basal rate of corresponding
peptide release was higher in the hypothalamus of the
ANA rats indicating an involvement of factors con-
w xtrolling translation andror transport processes 43 .
Interestingly, a higher NEP gene expression was
associated with a higher NEP activity in
tegmentumrcolliculi of AA rats compared to the
corresponding values found in ANA rats. The
tegmentumrcolliculi contains the VTA which is
known to have high concentrations of the compo-
nents of the endogenous opioid system. The higher
NEP activity found in tegmentumrcolliculi of AA
rats could lead to a higher degradation rate of
enkephalin in this area. Indeed, a lower content of
 .leu enkephalin was reported in the VTA of AA rats
w xcompared to the value found in ANA rats 13 .
Moreover, activation of dopaminergic neurons in the
VTA may be involved in the reinforcing effects of
w xdrugs of abuse 44 . Supporting this hypothesis,
ethanol self-infusion into the ventral tegmental area
w xby alcohol-preferring rats has been reported 45 . It is
proposed that ethanol may exert these effects indi-
rectly via various transmitter systems, including the
w xopioid system 46 . The reinforcing effects of
enkephalins are thought to be mediated mainly by d
opioid receptors in the VTA, where an activation of d
opioid receptors causes activation of the mesolimbic
dopamine pathway via disinhibition of GABA in-
terneurons. Therefore, the observed differences in the
NEP activity between the two lines of rats give
further evidence that neurobiological substrates in the
VTA may be genetically determined and contribute
to differences in ethanol drinking behavior.
In conclusion, the present study demonstrated the
first evidence for genetically determined differences
in some brain regions between AA and ANA rats in
the enkephalin-degrading enzymes ACE and NEP.
Further studies comparing gene expression and en-
zyme activity in the presence and after ethanol treat-
ment will provide more information on the impor-
tance of such differences between the AA and ANA
rats.
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